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Oral cancer (OC) is one of the 10 most diagnosed
cancers in the world. It is aggressive and difficult to
treat. Despite the achieved therapeutic advances, the 5
year survival rate has not changed in the past decade.
Understanding the basic molecular pathogenesis of OC
may give new opportunities for future treatments. Regu-
lators of the immune system such as CD40 [1]. and
CD26 [2] are believed to be involved in carcinogenesis
besides immunologic anti-tumour defence. The aim of
this study was to evaluate the influence of CD26/DPPIV
and CD40/CD40L cell expression in two OC cell lines
and treatment response.
For this two human OC cell lines BICR10 (in situ) and
HSC3 (metastatic) were incubated with cisplatin in dif-
ferent concentrations. Cell morphology was evaluated by
light microscopy and cell viability was estimated by ala-
mar blue test. Cell death CD26 and CD40/CD40L
expression was evaluated by flow cytometry and DPPIV
by luminescent assay.
Preliminary results show that BICR10 has higher
CD26/DPPIV levels and lower CD40/CD40L expression
than HSC3. However, after treatment with cisplatin
expression of CD40/CD40L and DPPIV increases in
both cell lines that could be related with apoptosis
detected by morphology and cytometry.
Our results suggest that CD40/CD40L and CD26/
DPPIV can be involved in OC development and drug
response and could constitute a new molecular target to
cancer diagnosis/prognosis and treatment.
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